Report cover image

Global Asthma Therapeutics Market Size study, by Drug Class, Treatment Type, Route of Administration (Inhaled, Oral, Injectable), Distribution Channel, End-use (Hospitals & clinics, ASCs, Homecare settings) and Regional Forecasts 2022-2032

Publisher Bizwit Research & Consulting
Published May 25, 2025
Length 285 Pages
SKU # BIZW20048096

Description

Global Asthma Therapeutics Market is valued approximately at USD 25.7 billion in 2023 and is anticipated to grow with a steady compound annual growth rate of more than 4.40% over the forecast period 2024–2032. Asthma, a chronic inflammatory disorder of the airways characterized by variable respiratory symptoms and airflow obstruction, continues to afflict millions worldwide. As the prevalence of environmental allergens, urban pollution, and genetic predispositions climbs, the demand for advanced and diversified therapeutic options is intensifying. Asthma therapeutics have progressed well beyond traditional bronchodilators, now encompassing biologics, anti-inflammatory agents, and targeted monoclonal antibodies tailored to phenotype-specific treatments—ushering in an era of personalized respiratory care.

Growing recognition of asthma’s heterogeneity and the expansion of asthma management guidelines have opened avenues for innovation in both maintenance and acute treatments. Robust R&D pipelines, fueled by increasing healthcare expenditure and strategic investments by key pharmaceutical giants, are driving the development of long-acting agents and next-generation biologics. Additionally, the expansion of mobile health platforms and smart inhaler devices are bridging gaps in medication adherence and monitoring, significantly contributing to therapeutic outcomes. However, reimbursement disparities and cost-intensive biologic therapies continue to challenge equitable access, particularly in low-resource settings.

The asthma therapeutics market is being buoyed by a mix of lifestyle factors and clinical demand. Urbanization, sedentary habits, and rising exposure to allergens have led to a spike in asthma diagnoses globally. Furthermore, the COVID-19 pandemic underscored the criticality of robust respiratory health, driving awareness and early intervention behaviors. Inhaled therapies remain the cornerstone of asthma management, but injectable biologics are rapidly gaining traction among patients with moderate-to-severe asthma unresponsive to conventional treatments. With leading players increasingly emphasizing patient-centric care models and integrated health platforms, the market is shifting toward a more adaptive and holistic framework.

Geographically, North America commands the lion’s share of the market, supported by a strong reimbursement network, clinical trial activity, and widespread asthma awareness programs. The U.S. leads this regional momentum through active FDA approvals and widespread biologic usage. Europe also maintains a sizable presence, particularly in nations with robust healthcare systems such as Germany, France, and the UK. Asia Pacific, however, is projected to register the fastest CAGR through 2032, driven by rising healthcare infrastructure investments, growing middle-class populations, and an alarming rise in pediatric asthma cases. In India and China, increasing availability of generic inhalers and government-led air quality interventions are helping boost access to treatments.

Meanwhile, Latin America and the Middle East & Africa are emerging as pivotal contributors to global market expansion. Regional growth is being supported by targeted healthcare funding, increased chronic disease screening programs, and improving pharmaceutical logistics networks. Countries like Brazil, Mexico, South Africa, and Saudi Arabia are prioritizing non-communicable disease management in national health policies, creating fertile ground for the expansion of asthma therapeutics. Furthermore, global market participants are increasingly forming local partnerships and licensing agreements to capitalize on untapped potential in these underserved yet growing economies.

Major market player included in this report are:
• AstraZeneca plc
• GlaxoSmithKline plc
• Sanofi S.A.
• Boehringer Ingelheim International GmbH
• Novartis AG
• Merck & Co., Inc.
• Cipla Ltd.
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Johnson & Johnson
• Amgen Inc.
• Viatris Inc.
• Chiesi Farmaceutici S.p.A.
• Roche Holding AG

The detailed segments and sub-segment of the market are explained below:

By Drug Class
• Corticosteroids
• Bronchodilators
• Leukotriene Modifiers
• Monoclonal Antibodies
• Others

By Treatment Type
• Long-Term Control Medications
• Quick-Relief Medications
• Others

By Route of Administration
• Inhaled
• Oral
• Injectable

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By End-use
• Hospitals & Clinics
• Ambulatory Surgical Centers (ASCs)
• Homecare Settings

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

Table of Contents

285 Pages
Chapter 1. Global Asthma Therapeutics Market Executive Summary
1.1. Global Asthma Therapeutics Market Size & Forecast (2022–2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Drug Class
1.3.2. By Treatment Type
1.3.3. By Route of Administration
1.3.4. By Distribution Channel
1.3.5. By End-use
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Asthma Therapeutics Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Patient’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Patient Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
– Historical year – 2022
– Base year – 2023
– Forecast period – 2024 to 2032
2.6. Currency Conversion Rates
Chapter 3. Global Asthma Therapeutics Market Dynamics
3.1. Market Drivers
3.1.1. Rising Prevalence of Allergens and Pollution
3.1.2. Expansion of Biologic and Targeted Therapies
3.1.3. Integration of Digital Health and Smart Inhalers
3.2. Market Challenges
3.2.1. High Cost of Biologics and Reimbursement Constraints
3.2.2. Patient Non-adherence and Device Misuse
3.2.3. Regulatory Hurdles for Novel Therapeutics
3.3. Market Opportunities
3.3.1. Emergence of Biosimilars and Generics
3.3.2. Growth in Homecare and Telehealth Services
3.3.3. Penetration into Emerging Markets
Chapter 4. Global Asthma Therapeutics Market Industry Analysis
4.1. Porter’s Five Forces Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s Model
4.1.7. Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Asthma Therapeutics Market Size & Forecasts by Drug Class 2022–2032
5.1. Segment Dashboard
5.2. Global Market: Drug Class Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. Corticosteroids
5.2.2. Bronchodilators
5.2.3. Leukotriene Modifiers
5.2.4. Monoclonal Antibodies
5.2.5. Others
Chapter 6. Global Asthma Therapeutics Market Size & Forecasts by Treatment Type 2022–2032
6.1. Segment Dashboard
6.2. Global Market: Treatment Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Long-Term Control Medications
6.2.2. Quick-Relief Medications
6.2.3. Others
Chapter 7. Global Asthma Therapeutics Market Size & Forecasts by Route of Administration 2022–2032
7.1. Segment Dashboard
7.2. Global Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)
7.2.1. Inhaled
7.2.2. Oral
7.2.3. Injectable
Chapter 8. Global Asthma Therapeutics Market Size & Forecasts by Distribution Channel 2022–2032
8.1. Segment Dashboard
8.2. Global Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Online Pharmacies
Chapter 9. Global Asthma Therapeutics Market Size & Forecasts by End-use 2022–2032
9.1. Segment Dashboard
9.2. Global Market: End-use Revenue Trend Analysis, 2022 & 2032 (USD Billion)
9.2.1. Hospitals & Clinics
9.2.2. Ambulatory Surgical Centers (ASCs)
9.2.3. Homecare Settings
Chapter 10. Global Asthma Therapeutics Market Size & Forecasts by Region 2022–2032
10.1. North America Market
10.1.1. U.S. Market
10.1.2. Canada Market
10.2. Europe Market
10.2.1. UK Market
10.2.2. Germany Market
10.2.3. France Market
10.2.4. Spain Market
10.2.5. Italy Market
10.2.6. Rest of Europe
10.3. Asia-Pacific Market
10.3.1. China Market
10.3.2. India Market
10.3.3. Japan Market
10.3.4. Australia Market
10.3.5. South Korea Market
10.3.6. Rest of Asia-Pacific
10.4. Latin America Market
10.4.1. Brazil Market
10.4.2. Mexico Market
10.4.3. Rest of Latin America
10.5. Middle East & Africa Market
10.5.1. Saudi Arabia Market
10.5.2. South Africa Market
10.5.3. Rest of Middle East & Africa
Chapter 11. Competitive Intelligence
11.1. Key Company SWOT Analysis
11.1.1. AstraZeneca plc
11.1.2. GlaxoSmithKline plc
11.1.3. Sanofi S.A.
11.2. Top Market Strategies
11.3. Company Profiles
11.3.1. AstraZeneca plc
11.3.1.1. Key Information
11.3.1.2. Overview
11.3.1.3. Financial (Subject to Data Availability)
11.3.1.4. Product Summary
11.3.1.5. Market Strategies
11.3.2. GlaxoSmithKline plc
11.3.3. Sanofi S.A.
11.3.4. Boehringer Ingelheim International GmbH
11.3.5. Novartis AG
11.3.6. Merck & Co., Inc.
11.3.7. Cipla Ltd.
11.3.8. Pfizer Inc.
11.3.9. Teva Pharmaceutical Industries Ltd.
11.3.10. Mylan N.V.
11.3.11. Johnson & Johnson
11.3.12. Amgen Inc.
11.3.13. Viatris Inc.
11.3.14. Chiesi Farmaceutici S.p.A.
11.3.15. Roche Holding AG
Chapter 12. Research Process
12.1. Research Process
12.1.1. Data Mining
12.1.2. Analysis
12.1.3. Market Estimation
12.1.4. Validation
12.1.5. Publishing
12.2. Research Attributes
List of Tables
TABLE 1. Global Asthma Therapeutics market, report scope
TABLE 2. Global market estimates & forecasts by Region 2022–2032 (USD Billion)
TABLE 3. Global market estimates & forecasts by Drug Class 2022–2032 (USD Billion)
TABLE 4. Global market estimates & forecasts by Treatment Type 2022–2032 (USD Billion)
TABLE 5. Global market estimates & forecasts by Route of Administration 2022–2032 (USD Billion)
TABLE 6. Global market estimates & forecasts by Distribution Channel 2022–2032 (USD Billion)
TABLE 7. Global market estimates & forecasts by End-use 2022–2032 (USD Billion)
TABLE 8. U.S. market estimates & forecasts, 2022–2032 (USD Billion)
TABLE 9. U.S. market estimates & forecasts by segment 2022–2032 (USD Billion)
TABLE 10. Canada market estimates & forecasts, 2022–2032 (USD Billion)
TABLE 11. Europe market estimates & forecasts, 2022–2032 (USD Billion)
TABLE 12. Asia-Pacific market estimates & forecasts, 2022–2032 (USD Billion)
TABLE 13. Latin America market estimates & forecasts, 2022–2032 (USD Billion)
TABLE 14. Middle East & Africa market estimates & forecasts, 2022–2032 (USD Billion)
TABLE 15. Market share of top companies, 2023 (%)
TABLE 16. Pricing analysis by region
TABLE 17. R&D expenditure trend
TABLE 18. Distribution channel mix
TABLE 19. Top product launches timeline
TABLE 20. Key regulatory approvals timeline
List of Figures
FIGURE 1. Global market, research methodology
FIGURE 2. Global market, estimation techniques
FIGURE 3. Global market size estimates & forecast methods
FIGURE 4. Global market, key trends 2023
FIGURE 5. Global market, growth prospects 2022–2032
FIGURE 6. Global market, Porter’s Five Forces model
FIGURE 7. Global market, PESTEL analysis
FIGURE 8. Global market, value chain analysis
FIGURE 9. Global market by segment, 2022 & 2032 (USD Billion)
FIGURE 10. Global market by region, 2022 & 2032 (USD Billion)
FIGURE 11. North America market 2022 & 2032 (USD Billion)
FIGURE 12. Europe market 2022 & 2032 (USD Billion)
FIGURE 13. Asia-Pacific market 2022 & 2032 (USD Billion)
FIGURE 14. Latin America market 2022 & 2032 (USD Billion)
FIGURE 15. Middle East & Africa market 2022 & 2032 (USD Billion)
FIGURE 16. Company market share analysis (2023)
FIGURE 17. Smart inhaler adoption trends
FIGURE 18. Biologics pipeline overview
FIGURE 19. Reimbursement landscape map
FIGURE 20. Regional air quality and asthma incidence correlation

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us